• Spectral Medical and Vantive reported that complete results from the Phase 3 Tigris trial of Polymyxin B Hemoadsorption $(PMX)$ in adults with endotoxic septic shock were published in The Lancet Respiratory Medicine.
• The primary endpoint analysis reported a 95.3% probability of benefit for PMX on 28-day mortality, with an adjusted absolute risk reduction of 10.3%.
• The key secondary endpoint analysis reported a 99.4% probability of benefit on 90-day mortality, with an adjusted absolute risk reduction of 15.5%.
• The company said the findings were previously reported in August 2025 and will be presented in the future at the Society of Critical Care Medicine Congress in Chicago on March 24, 2026.
• Safety outcomes during the treatment period showed no significant difference in adverse events between PMX plus standard of care and standard of care alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spectral Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603240700PRIMZONEFULLFEED9677294) on March 24, 2026, and is solely responsible for the information contained therein.